Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology firm dedicated to the innovation, advancement, and commercialization of new technologies within the biotech sector. Its primary therapeutic focus revolves around a portfolio of product candidates, notably EP-104IAR, which is currently undergoing a Phase III clinical trial to address significant unmet medical needs, particularly offering pain relief for knee osteoarthritis. Another key candidate, EP-104GI, is progressing through Phase II trials for the treatment of eosinophilic esophagitis. Additionally, EP-104 is in preclinical development, exploring its potential for various inflammatory joint conditions, benign esophageal strictures, and applications via epidural delivery. Beyond these, the company is also developing drug candidates in the field of oncology. Originally established as Plaza Capital Partners Inc., the company rebranded to Eupraxia Pharmaceuticals Inc. in May 2012. Incorporated in 2011, Eupraxia Pharmaceuticals Inc. operates from its headquarters in Victoria, Canada.
globenewswire.comEupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conferenceglobenewswire.comMay 28
globenewswire.comEupraxia Pharmaceuticals Reports First Quarter 2026 Financial Resultsglobenewswire.comMay 12
globenewswire.comEupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Weekglobenewswire.comMay 6
globenewswire.comEupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)globenewswire.comMay 5
globenewswire.comEupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officerglobenewswire.comMay 1